Results 21 to 30 of about 381 (103)

<i>TAC1b</i> mutation in <i>Candida auris</i> decreases manogepix susceptibility owing to increased <i>CDR1</i> expression. [PDF]

Antimicrob Agents Chemother
ABSTRACT Candida auris is an emerging pathogenic fungus that is highly resistant to existing antifungal drugs. Manogepix is a novel antifungal agent that exerts antifungal activity by inhibiting glycosylphosphatidylinositol anchor biosynthesis. Although the mechanisms of resistance of
Hirayama T, Miyazaki T, Tanaka R, Kitahori N, Yoshida M, Takeda K, Ide S, Iwanaga N, Tashiro M, Takazono T, Izumikawa K, Yanagihara K, Makimura K, Tsukamoto K, Mukae H.   +14 more
europepmc   +5 more sources

Novel Antifungals and Aspergillus Section Terrei with Potpourri Susceptibility Profiles to Conventional Antifungals

Journal of Fungi, 2023
The epidemiology of invasive fungal infections (IFIs) is currently changing, driven by aggressive immunosuppressive therapy, leading to an expanded spectrum of patients at risk of IFIs.
Roya Vahedi-Shahandashti, Jos Houbraken, Mike Birch, Cornelia Lass-Flörl   +3 more
doaj   +1 more source

Invasive pulmonary aspergillosis in the intensive care unit: current challenges and best practices

APMIS, Volume 131, Issue 11, Page 654-667, November 2023., 2023
The prevalence of invasive pulmonary aspergillosis (IPA) is growing in critically ill patients in the intensive care unit (ICU). It is increasingly recognized in immunocompetent hosts and immunocompromised ones. IPA frequently complicates both severe influenza and severe coronavirus disease 2019 (COVID‐19) infection.
Sarah Gaffney, Dearbhla M. Kelly, Puteri Maisarah Rameli, Eoin Kelleher, Ignacio Martin‐Loeches   +4 more
wiley   +1 more source

Pharmacodynamics, Mechanisms of Action and Resistance, and Spectrum of Activity of New Antifungal Agents

Journal of Fungi, 2022
Several new antifungals are currently in late-stage development, including those with novel pharmacodynamics/mechanisms of action that represent new antifungal classes (manogepix, olorofim, ATI-2307, GR-2397). Others include new agents within established
Nathan P. Wiederhold
doaj   +1 more source

In vitro effects of the new antifungal compound manogepix (APX001) against the three most clinically relevant species of Sporothrix. [PDF]

Braz J Microbiol
Sporotrichosis is an endemic mycosis that pose significant public health challenges, particularly in Brazil, where zoonotic transmission has increased the number of cases in several regions of the country. The disease is caused by Sporothrix genus, with S. brasiliensis, S. schenckii, and S. globosa as the major agents. The currently available therapies
Almeida-Silva F, Marques FPN, Tenório-Alvarenga PH, Poester VR, Xavier MO, Zancopé-Oliveira RM, Almeida-Paes R.   +6 more
europepmc   +3 more sources

Antifungal chemotherapies and immunotherapies for the future

Parasite Immunology, Volume 45, Issue 2, February 2023., 2023
Abstract Human fungal pathogens cause a broad plethora of infections, spanning cutaneous dermatophytoses to invasive infections in immunocompromised hosts. As eukaryotic pathogens are capable of morphotype switching, they present unique challenges both for drug development and the immunological response.
Darius Armstrong‐James
wiley   +1 more source

Enhanced Efflux Pump Expression in Candida Mutants Results in Decreased Manogepix Susceptibility

Antimicrobial Agents and Chemotherapy, 2020
Manogepix is a broad-spectrum antifungal agent that inhibits glycosylphosphatidylinositol (GPI) anchor biosynthesis. Using whole-genome sequencing, we characterized two efflux-mediated mechanisms in the fungal pathogens Candida albicans and Candida parapsilosis that resulted in decreased ...
Sean D. Liston, Luke Whitesell, Mili Kapoor, Karen Joy Shaw, Leah E. Cowen   +4 more
openaire   +2 more sources

Candida auris in Austria—What Is New and What Is Different

Journal of Fungi, 2023
Candida auris is a novel and emerging pathogenic yeast which represents a serious global health threat. Since its first description in Japan 2009, it has been associated with large hospital outbreaks all over the world and is often resistant to more than
Kathrin Spettel, Richard Kriz, Christine Wu, Lukas Achter, Stefan Schmid, Sonia Galazka, Brigitte Selitsch, Iris Camp, Athanasios Makristathis, Heimo Lagler, Birgit Willinger   +10 more
doaj   +1 more source

Recent Antifungal Pipeline Developments against Candida auris: A Systematic Review

Journal of Fungi, 2022
The alarming spread and impact of multidrug-resistant Candida auris infections alongside the limited therapeutic options have prompted the development of new antifungals.
Rogelio de J. Treviño-Rangel, Gloria M. González, Alexandra M. Montoya, Olga C. Rojas, Mariana Elizondo-Zertuche, Neri A. Álvarez-Villalobos   +5 more
doaj   +1 more source

Fosmanogepix: A Review of the First-in-Class Broad Spectrum Agent for the Treatment of Invasive Fungal Infections

Journal of Fungi, 2020
Fosmanogepix is a first-in-class antifungal currently in Phase 2 clinical trials for the treatment of invasive fungal infections caused by Candida, Aspergillus and rare molds. Fosmanogepix is the N-phosphonooxymethylene prodrug of manogepix, an inhibitor
Karen Joy Shaw, Ashraf S. Ibrahim
doaj   +1 more source